Works by Chari, Ajai

Results: 135
    1

    Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma.

    Published in:
    EJHaem, 2021, v. 2, n. 1, p. 48, doi. 10.1002/jha2.120
    By:
    • Richardson, Paul G.;
    • Jagannath, Sundar;
    • Chari, Ajai;
    • Vogl, Dan T.;
    • Dimopoulos, Meletios A.;
    • Moreau, Philippe;
    • Dingli, David;
    • Wei, Lee‐Jen;
    • Richter, Joshua;
    • Biran, Noa;
    • Siegel, David;
    • Reichmann, William;
    • Li, Lingling;
    • Tang, Shijie;
    • Saint‐Martin, Jean‐Richard;
    • Joshi, Anita;
    • Kauffman, Michael;
    • Shah, Jatin;
    • Shacham, Sharon;
    • Lonial, Sagar
    Publication type:
    Article
    2
    3
    4

    Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.

    Published in:
    Advances in Therapy, 2021, v. 38, n. 2, p. 1328, doi. 10.1007/s12325-020-01601-w
    By:
    • Chari, Ajai;
    • Munder, Markus;
    • Weisel, Katja;
    • Jenner, Matthew;
    • Bygrave, Ceri;
    • Petrucci, Maria Teresa;
    • Boccadoro, Mario;
    • Cavo, Michele;
    • van de Donk, Niels W. C. J.;
    • Turgut, Mehmet;
    • Demirkan, Fatih;
    • Karadogan, Ihsan;
    • Libby, Edward;
    • Kleiman, Robert;
    • Kuppens, Steven;
    • Bandekar, Rajesh;
    • Neff, Tobias;
    • Heuck, Christoph;
    • Qi, Ming;
    • Clemens, Pamela L.
    Publication type:
    Article
    5
    6

    Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN.

    Published in:
    American Journal of Hematology, 2024, v. 99, n. 7, p. 1257, doi. 10.1002/ajh.27326
    By:
    • Silbermann, Rebecca;
    • Laubach, Jacob;
    • Kaufman, Jonathan L.;
    • Sborov, Douglas W.;
    • Reeves, Brandi;
    • Rodriguez, Cesar;
    • Chari, Ajai;
    • Costa, Luciano J.;
    • Anderson, Larry D.;
    • Nathwani, Nitya;
    • Shah, Nina;
    • Bumma, Naresh;
    • Holstein, Sarah A.;
    • Costello, Caitlin;
    • Jakubowiak, Andrzej;
    • Orlowski, Robert Z.;
    • Shain, Kenneth H.;
    • Cowan, Andrew J.;
    • Gries, Katharine S.;
    • Pei, Huiling
    Publication type:
    Article
    7

    Trial designs and endpoints for immune therapies in multiple myeloma.

    Published in:
    American Journal of Hematology, 2023, v. 98, p. S35, doi. 10.1002/ajh.26753
    By:
    • Lancman, Guido;
    • Moshier, Erin;
    • Cho, Hearn Jay;
    • Parekh, Samir;
    • Richard, Shambavi;
    • Richter, Joshua;
    • Rodriguez, Cesar;
    • Rossi, Adriana;
    • Sanchez, Larysa;
    • Jagannath, Sundar;
    • Chari, Ajai
    Publication type:
    Article
    8

    Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

    Published in:
    American Journal of Hematology, 2021, v. 96, n. 9, p. 1120, doi. 10.1002/ajh.26261
    By:
    • Richard, Shambavi;
    • Chari, Ajai;
    • Delimpasi, Sosana;
    • Simonova, Maryana;
    • Spicka, Ivan;
    • Pour, Ludek;
    • Kriachok, Iryna;
    • Dimopoulos, Meletios A.;
    • Pylypenko, Halyna;
    • Auner, Holger W.;
    • Leleu, Xavier;
    • Usenko, Ganna;
    • Hajek, Roman;
    • Benjamin, Reuben;
    • Dolai, Tuphan Kanti;
    • Sinha, Dinesh Kumar;
    • Venner, Christopher P.;
    • Garg, Mamta;
    • Stevens, Don Ambrose;
    • Quach, Hang
    Publication type:
    Article
    9

    Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

    Published in:
    American Journal of Hematology, 2021, v. 96, n. 1, p. E5, doi. 10.1002/ajh.26010
    By:
    • Cornell, Robert;
    • Hari, Parameswaran;
    • Tang, Shijie;
    • Biran, Noa;
    • Callander, Natalie;
    • Chari, Ajai;
    • Chhabra, Saurabh;
    • Fiala, Mark A.;
    • Gahvari, Zhubin;
    • Gandhi, Ujjawal;
    • Godby, Kelly;
    • Gupta, Ridhi;
    • Jagannath, Sundar;
    • Jagosky, Megan;
    • Kang, Yubin;
    • Kansagra, Ankit;
    • Kauffman, Michael;
    • Kodali, Saranya;
    • Kumar, Shaji K.;
    • Lakshman, Arjun
    Publication type:
    Article
    10

    Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>.

    Published in:
    American Journal of Hematology, 2020, v. 95, n. 2, p. E51, doi. 10.1002/ajh.25695
    By:
    • Barley, Kevin;
    • Sanchez, Larysa;
    • Cho, Hearn J.;
    • Parekh, Samir;
    • Madduri, Deepu;
    • Richter, Joshua;
    • Isola, Luis;
    • Goldstein, Talia;
    • Dhadwal, Amishi;
    • Zarychta, Katarzyna;
    • Sanchez, Gillian Morgan;
    • Catamero, Donna;
    • Verina, Daniel;
    • Florendo, Erika;
    • Yum, Moon‐hee;
    • La, Lisa;
    • Gullie, Jude;
    • Chan, Elaine;
    • Jagannath, Sundar;
    • Chari, Ajai
    Publication type:
    Article
    11
    12
    13
    14
    15
    16

    Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01088-6
    By:
    • Chari, Ajai;
    • Kaufman, Jonathan L.;
    • Laubach, Jacob;
    • Sborov, Douglas W.;
    • Reeves, Brandi;
    • Rodriguez, Cesar;
    • Silbermann, Rebecca;
    • Costa, Luciano J.;
    • Anderson Jr, Larry D.;
    • Nathwani, Nitya;
    • Shah, Nina;
    • Bumma, Naresh;
    • Holstein, Sarah A.;
    • Costello, Caitlin;
    • Jakubowiak, Andrzej;
    • Wildes, Tanya M.;
    • Orlowski, Robert Z.;
    • Shain, Kenneth H.;
    • Cowan, Andrew J.;
    • Pei, Huiling
    Publication type:
    Article
    17

    Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01030-w
    By:
    • Callander, Natalie S.;
    • Silbermann, Rebecca;
    • Kaufman, Jonathan L.;
    • Godby, Kelly N.;
    • Laubach, Jacob;
    • Schmidt, Timothy M.;
    • Sborov, Douglas W.;
    • Medvedova, Eva;
    • Reeves, Brandi;
    • Dhakal, Binod;
    • Rodriguez, Cesar;
    • Chhabra, Saurabh;
    • Chari, Ajai;
    • Bal, Susan;
    • Anderson Jr, Larry D.;
    • Dholaria, Bhagirathbhai R.;
    • Nathwani, Nitya;
    • Hari, Parameswaran;
    • Shah, Nina;
    • Bumma, Naresh
    Publication type:
    Article
    18

    GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00966-9
    By:
    • Rodriguez-Otero, Paula;
    • van de Donk, Niels W. C. J.;
    • Pillarisetti, Kodandaram;
    • Cornax, Ingrid;
    • Vishwamitra, Deeksha;
    • Gray, Kathleen;
    • Hilder, Brandi;
    • Tolbert, Jaszianne;
    • Renaud, Thomas;
    • Masterson, Tara;
    • Heuck, Christoph;
    • Kane, Colleen;
    • Verona, Raluca;
    • Moreau, Philippe;
    • Bahlis, Nizar;
    • Chari, Ajai
    Publication type:
    Article
    19
    20

    GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00966-9
    By:
    • Rodriguez-Otero, Paula;
    • van de Donk, Niels W. C. J.;
    • Pillarisetti, Kodandaram;
    • Cornax, Ingrid;
    • Vishwamitra, Deeksha;
    • Gray, Kathleen;
    • Hilder, Brandi;
    • Tolbert, Jaszianne;
    • Renaud, Thomas;
    • Masterson, Tara;
    • Heuck, Christoph;
    • Kane, Colleen;
    • Verona, Raluca;
    • Moreau, Philippe;
    • Bahlis, Nizar;
    • Chari, Ajai
    Publication type:
    Article
    21

    Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00805-x
    By:
    • Moreau, Philippe;
    • Chari, Ajai;
    • Oriol, Albert;
    • Martinez-Lopez, Joaquin;
    • Haenel, Mathias;
    • Touzeau, Cyrille;
    • Ailawadhi, Sikander;
    • Besemer, Britta;
    • de la Rubia Comos, Javier;
    • Encinas, Cristina;
    • Mateos, Maria-Victoria;
    • Salwender, Hans;
    • Rodriguez-Otero, Paula;
    • Hulin, Cyrille;
    • Karlin, Lionel;
    • Sureda Balari, Anna;
    • Bargay, Joan;
    • Benboubker, Lotfi;
    • Rosiñol, Laura;
    • Tarantolo, Stefano
    Publication type:
    Article
    22

    Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

    Published in:
    2023
    By:
    • Moreau, Philippe;
    • Chari, Ajai;
    • Oriol, Albert;
    • Martinez-Lopez, Joaquin;
    • Haenel, Mathias;
    • Touzeau, Cyrille;
    • Ailawadhi, Sikander;
    • Besemer, Britta;
    • de la Rubia Comos, Javier;
    • Encinas, Cristina;
    • Mateos, Maria-Victoria;
    • Salwender, Hans;
    • Rodriguez-Otero, Paula;
    • Hulin, Cyrille;
    • Karlin, Lionel;
    • Sureda Balari, Anna;
    • Bargay, Joan;
    • Benboubker, Lotfi;
    • Rosiñol, Laura;
    • Tarantolo, Stefano
    Publication type:
    Letter
    23

    Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.

    Published in:
    2022
    By:
    • Nooka, Ajay K.;
    • Kaufman, Jonathan L.;
    • Rodriguez, Cesar;
    • Jakubowiak, Andrzej;
    • Efebera, Yvonne;
    • Reeves, Brandi;
    • Wildes, Tanya;
    • Holstein, Sarah A.;
    • Anderson Jr, Larry D.;
    • Badros, Ashraf;
    • Shune, Leyla;
    • Chari, Ajai;
    • Pei, Huiling;
    • Cortoos, Annelore;
    • Patel, Sharmila;
    • Bartlett, J. Blake;
    • Vermeulen, Jessica;
    • Lin, Thomas S.;
    • Richardson, Paul G.;
    • Voorhees, Peter
    Publication type:
    Letter
    24

    Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 2, p. 1, doi. 10.1038/s41408-021-00432-4
    By:
    • Terpos, Evangelos;
    • Mikhael, Joseph;
    • Hajek, Roman;
    • Chari, Ajai;
    • Zweegman, Sonja;
    • Lee, Hans C.;
    • Mateos, María-Victoria;
    • Larocca, Alessandra;
    • Ramasamy, Karthik;
    • Kaiser, Martin;
    • Cook, Gordon;
    • Weisel, Katja C.;
    • Costello, Caitlin L.;
    • Elliott, Jennifer;
    • Palumbo, Antonio;
    • Usmani, Saad Z.
    Publication type:
    Article
    25

    Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 11, p. 1, doi. 10.1038/s41408-020-00375-2
    By:
    • Kaufman, Jonathan L.;
    • Dimopoulos, Meletios A.;
    • White, Darrell;
    • Benboubker, Lotfi;
    • Cook, Gordon;
    • Leiba, Merav;
    • Morton, James;
    • Joy Ho, P.;
    • Kim, Kihyun;
    • Takezako, Naoki;
    • Moreau, Philippe;
    • Sutherland, Heather J.;
    • Magen, Hila;
    • Iida, Shinsuke;
    • Kim, Jin Seok;
    • Miles Prince, H.;
    • Cochrane, Tara;
    • Oriol, Albert;
    • Bahlis, Nizar J.;
    • Chari, Ajai
    Publication type:
    Article
    26

    Selinexor for the treatment of multiple myeloma.

    Published in:
    Expert Opinion on Pharmacotherapy, 2020, v. 21, n. 4, p. 399, doi. 10.1080/14656566.2019.1707184
    By:
    • Podar, Klaus;
    • Shah, Jatin;
    • Chari, Ajai;
    • Richardson, Paul G;
    • Jagannath, Sundar
    Publication type:
    Article
    27

    P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL‐1.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970472.64690.4e
    By:
    • Rasche, Leo;
    • Schinke, Carolina;
    • Chari, Ajai;
    • Lipe, Brea C.;
    • Lavi, Noa;
    • Rodríguez‐Otero, Paula;
    • Vishwamitra, Deeksha;
    • Skerget, Sheri;
    • Verona, Raluca;
    • MA, Xuewen;
    • Khedkar, Sheetal;
    • Hilder, Brandi;
    • Masterson, Tara;
    • Campagna, Michela;
    • Renaud, Thomas;
    • Tolbert, Jaszianne;
    • Heuck, Christoph;
    • Smit, Damiette;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    28
    29

    P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC‐1 STUDY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970428.90600.b0
    By:
    • Bhutani, Manisha;
    • Garfall, Alfred;
    • Uttervall, Katarina;
    • Usmani, Saad Z;
    • Karlin, Lionel;
    • Benboubker, Lotfi;
    • Nahi, Hareth;
    • San Miguel, Jesús;
    • Trancucci, Danielle;
    • Qi, Keqin;
    • Stephenson, Tara;
    • Perales‐Puchalt, Alfredo;
    • Chastain, Katherine;
    • Chari, Ajai
    Publication type:
    Article
    30

    S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM‐2 RESULTS.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967680.90062.ca
    By:
    • Bahlis, Nizar J;
    • Weisel, Katja;
    • Mateos, Maria‐Victoria;
    • Goldschmidt, Hartmut;
    • Martin, Tom;
    • Morillo, Daniel;
    • Reece, Donna;
    • Rodríguez‐Otero, Paula;
    • Bhutani, Manisha;
    • D’souza, Anita;
    • Oriol, Albert;
    • Rosiñol Dachs, Laura;
    • Dholaria, Bhagirathbhai;
    • Bakshi, Kalpana;
    • Kang, Lijuan;
    • Vandenberk, Lien;
    • Smit, Damiette;
    • Wäsch, Ralph;
    • van de Donk, Niels W.C.J.;
    • Chari, Ajai
    Publication type:
    Article
    31

    S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

    Published in:
    2023
    By:
    • Touzeau, Cyrille;
    • Schinke, Carolina;
    • Minnema, Monique;
    • van de Donk, Niels W.C.J.;
    • Rodríguez-Otero, Paula;
    • Mateos, Maria-Victoria;
    • Rasche, Leo;
    • Ye, Jing Christine;
    • Vishwamitra, Deeksha;
    • MA, Xuewen;
    • Qin, Xiang;
    • Campagna, Michela;
    • Masterson, Tara;
    • Hilder, Brandi;
    • Tolbert, Jaszianne;
    • Renaud, Thomas;
    • Goldberg, Jenna;
    • Heuck, Christoph;
    • Chari, Ajai
    Publication type:
    Abstract
    32
    33

    Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 2, p. 468, doi. 10.1080/10428194.2022.2148221
    By:
    • Nahi, Hareth;
    • Usmani, Saad Z.;
    • Mateos, Maria-Victoria;
    • van de Donk, Niels W. C. J.;
    • Oriol, Albert;
    • Plesner, Torben;
    • Bandyopadhyay, Nibedita;
    • Hellemans, Peter;
    • Tromp, Brenda;
    • Nnane, Ivo;
    • Zemlickis, Donna;
    • Chari, Ajai;
    • Moreau, Philippe
    Publication type:
    Article
    34

    Efficacy and safety of weekly carfilzomib (70 mg/m<sup>2</sup>), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.

    Published in:
    Leukemia & Lymphoma, 2021, v. 62, n. 2, p. 358, doi. 10.1080/10428194.2020.1832672
    By:
    • Leleu, Xavier;
    • Beksac, Meral;
    • Chou, Takaaki;
    • Dimopoulos, Meletios;
    • Yoon, Sung-Soo;
    • Prince, H. Miles;
    • Pour, Ludek;
    • Shelekhova, Tatiana;
    • Chari, Ajai;
    • Khurana, Monica;
    • Zhang, Jianqi;
    • Obreja, Mihaela;
    • Qi, Ming;
    • Oriol, Albert;
    • Siegel, David
    Publication type:
    Article
    35

    Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.

    Published in:
    Leukemia & Lymphoma, 2018, v. 59, n. 11, p. 2588, doi. 10.1080/10428194.2018.1443337
    By:
    • Chari, Ajai;
    • Larson, Sarah;
    • Holkova, Beata;
    • Cornell, Robert F.;
    • Gasparetto, Cristina;
    • Karanes, Chatchada;
    • Matous, Jeffrey V.;
    • Niesvizky, Ruben;
    • Valent, Jason;
    • Lunning, Matthew;
    • Usmani, Saad Z.;
    • Anderson, Larry D.;
    • Chang, Lipo;
    • Lee, Yihua;
    • Pak, Yvonne;
    • Salman, Zeena;
    • Graef, Thorsten;
    • Bilotti, Elizabeth;
    • Chhabra, Saurabh
    Publication type:
    Article
    36
    37
    38
    39
    40

    Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial.

    Published in:
    Cancer (0008543X), 2023, v. 129, n. 23, p. 3746, doi. 10.1002/cncr.34987
    By:
    • Nooka, Ajay K.;
    • Cohen, Adam D.;
    • Lee, Hans C.;
    • Badros, Ashraf;
    • Suvannasankha, Attaya;
    • Callander, Natalie;
    • Abdallah, Al‐Ola;
    • Trudel, Suzanne;
    • Chari, Ajai;
    • Libby, Edward N.;
    • Chaudhry, Maria;
    • Hultcrantz, Malin;
    • Kortüm, K. Martin;
    • Popat, Rakesh;
    • Sborov, Douglas;
    • Hakim, Shawn;
    • Lewis, Eric;
    • Gorsh, Boris;
    • Bhushan, Bharat;
    • McKeown, Astrid
    Publication type:
    Article
    41
    42
    43
    44
    45

    Diagnostic Advances in Multiple Myeloma.

    Published in:
    Current Hematologic Malignancy Reports, 2016, v. 11, n. 2, p. 111, doi. 10.1007/s11899-016-0314-5
    By:
    • Barley, Kevin;
    • Chari, Ajai
    Publication type:
    Article
    46
    47
    48

    Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study.

    Published in:
    Cancer (0008543X), 2021, v. 127, n. 22, p. 4198, doi. 10.1002/cncr.33809
    By:
    • Lonial, Sagar;
    • Lee, Hans C.;
    • Badros, Ashraf;
    • Trudel, Suzanne;
    • Nooka, Ajay K.;
    • Chari, Ajai;
    • Abdallah, Al‐Ola;
    • Callander, Natalie;
    • Sborov, Douglas;
    • Suvannasankha, Attaya;
    • Weisel, Katja;
    • Voorhees, Peter M.;
    • Womersley, Lynsey;
    • Baron, January;
    • Piontek, Trisha;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Gupta, Ira;
    • Cohen, Adam D.
    Publication type:
    Article
    49

    Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.

    Published in:
    2021
    By:
    • Martin, Thomas G.;
    • Shah, Nina;
    • Richter, Joshua;
    • Vesole, David H.;
    • Wong, Sandy W.;
    • Huang, Chiung‐Yu;
    • Madduri, Deepu;
    • Jagannath, Sundar;
    • Siegel, David S.;
    • Biran, Noa;
    • Wolf, Jeffrey L.;
    • Parekh, Samir;
    • Cho, Hearn J.;
    • Munster, Pamela;
    • Richard, Shambavi;
    • Ziti‐Ljajic, Samira;
    • Chari, Ajai;
    • Huang, Chiung-Yu;
    • Ziti-Ljajic, Samira
    Publication type:
    journal article
    50